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Beyond BCG: boosting strategies with viral vector vaccines
Mycobacterium tuberculosis (Mtb) is the causative agent for
tuberculosis disease (TB). In 2013 9M people (1,1 HIV+) developed TB
and 1,5M (360 000 HIV+) died from it. There were also registered 480
000 MDR-TB cases, three times higher than in 1990. HIV-TB
coinfection and the increase of drug resistances have become a
concern towards controlling the disease.
However, it's not all bad news. From 1990 to 2013 the mortality rate
and prevalence have decreased a 45 and 41% respectively, and 37M
lives were saved from 2000 to 2013 due to prevention programms and
TB treatment.
Introduction
The immune response required against Mtb is cell-mediated with T lymphocytes and mononuclear phagocytes (MP). The T-cell response is biased to the Th1
pole. The CD4+ and CD8+ T-cells both secrete INF-γ and TNF-α, that will activate the MP, whereas CD8+ also produce perforins, granulysins and granzyms that
will harm the bacilli. The Th17 response is involved in the early defense and adaptive immunity against TB, it also may be a Th1 recruiter and therefore help
accelerate the bacterial clearance. However, if maintained for long periods can induce pathology due to inflammation. The induction of long-lived memory T-
cells is paramount in terms of control of the bacilli, this may be the major problem in the production of a TB vaccine.
Immune response to Mtb
 In order to control and eventually eradicate TB there is a
need for better diagnostics, treatments and an
efficacious vaccine.
 In every trial conducted to date MVA85A, AdAg85a and
Ad35/AERAS 402 have proved to be safe and
immunogenic, but not efficacious.
 Concerns on adenoviral vectors regarding the potency
for dampening the immune response due to the
induction of neutralizing antibodies have been overcome
 Further investigation is required.
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Vaccination
The Bacille Calmette-Guérin (BCG) is the only vaccine available for
preventing TB. The countries with the highest TB burden have a BCG
vaccination policy. BCG only confers partial protection in children.
Thus, in order to maximize the protection range a secondary boost is
needed.
Viral vector vaccines as boosters of
BCG immunization are an attractive
approach. Replication-deficient
variants of pathogenic virus such as
the modified vaccinia virus (MVA) and
adenovirus (Ad) are the most
clinically advanced viral vectors.
Image 1: Vaccinia virus and Adenovirus 
